Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1006 to 1020 of 1094 results for infections

  1. Sexually transmitted infections and under-18 conceptions: prevention (PH3)

    This guidance has been updated and replaced by NICE guideline NG221.

  2. Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy (TA1126)

    Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.

  3. Leukomed Sorbact for preventing surgical site infection (MTG55)

    We have moved Medical technologies guidance 55 to become HealthTech guidance 567. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  4. Plus Sutures for preventing surgical site infection (MTG59)

    We have moved Medical technologies guidance 59 to become HealthTech guidance 586. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  5. Leukomed Sorbact for preventing surgical site infection (MIB197)

    This advice has been updated and replaced by NICE healthtech guidance 567.

  6. Plus Sutures for preventing surgical site infection (MIB204)

    This advice has been updated and replaced by NICE healthtech guidance guidance 586.

  7. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  8. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  9. Brain tumours (primary) and brain metastases in over 16s (NG99)

    This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.

  10. Twin and triplet pregnancy (NG137)

    This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.

  11. The SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system (MIB21)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of

  12. Rehabilitation after traumatic injury (NG211)

    This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.

  13. Symptoms and signs of recurrent UTI:  Do the symptoms and signs of UTI in babies, children and young people aged under 16 years differ in those with a history of recurrent UTIs compared with those without a history of recurrent UTI?

    Source guidance details Comes from guidance Urinary tract infection in under 16s: diagnosis and management Number NG224 Date

  14. Symptoms and signs of long-term (chronic) UTI: What symptoms and signs do children and young people with long-term (chronic) UTI report and what do they perceive is the impact on their health and quality of life?

    Source guidance details Comes from guidance Urinary tract infection in under 16s: diagnosis and management Number NG224 Date

  15. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)

    Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.